Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?

BackgroundA significant amount of common variable immunodeficiency (CVID) patients manifest with autoimmunity. Particularly, autoimmune thrombocytopenia (AITP) is commonly seen. Intravenous immunoglobulins (IVIG) are an established treatment option for both, CVID and AITP. Nonetheless, due to fewer...

Full description

Bibliographic Details
Main Authors: Philipp Scheuerlein, Larissa Pietsch, Nadezhda Camacho-Ordonez, Veronika Reiser, Smita Patel, Siobhan O. Burns, Klaus Warnatz, Bodo Grimbacher
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-07-01
Series:Frontiers in Immunology
Subjects:
common variable immunodeficiency
autoimmune thrombocytopenia
intravenous immunoglobulin
subcutaneous immunoglobulin
immunoglobulin replacement therapy
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.01656/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.01656/full

Similar Items